Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147448 | 0.87 | SIGMAR1 (0.50) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL10142868 | 0.84 | SIGMAR1 (0.55) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL13484229 | 0.84 | SIGMAR1 (0.50) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL13264430 | 0.81 | LMNA (0.47) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL23858257 | 0.80 | SIGMAR1 (0.50) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL14211699 | 0.80 | SIGMAR1 (0.50) | SIGMAR1ACHEMC4RPNMTDRD4 | |
| SCHEMBL8344719 | 0.80 | LMNA (0.50) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL5621315 | 0.79 | SIGMAR1 (0.57) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL14969763 | 0.79 | LMNA (0.49) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL14382631 | 0.78 | ACHE (0.47) | SIGMAR1LMNAPOLBACHEPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | SIGMAR1 670/4885LMNA 2947/4885POLB 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.